RT Journal Article
SR Electronic
T1 Adverse events reported during weekly isoniazid-rifapentine (3HP) tuberculosis preventive treatment among people living with HIV in Uganda
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.08.24311632
DO 10.1101/2024.08.08.24311632
A1 Kadota, Jillian L.
A1 Musinguzi, Allan
A1 Aschmann, Hélène E.
A1 Akello, Lydia
A1 Welishe, Fred
A1 Nakimuli, Jane
A1 Berger, Christopher A.
A1 Kiwanuka, Noah
A1 Phillips, Patrick PJ
A1 Katamba, Achilles
A1 Dowdy, David W.
A1 Cattamanchi, Adithya
A1 Semitala, Fred C.
YR 2024
UL http://medrxiv.org/content/early/2024/08/09/2024.08.08.24311632.abstract
AB Background Short-course tuberculosis (TB) prevention regimens, including 12 weeks of isoniazid and rifapentine (3HP), are increasingly used in high TB-burden countries. Despite established safety and tolerability in efficacy trials, 3HP-related adverse events (AE) could differ in routine settings. Real-world data on AE type, frequency, and timing is crucial for health systems considering 3HP programmatic scale-up.Methods We reviewed AEs among people living with HIV (PLHIV) participating in a pragmatic implementation trial of facilitated 3HP taken by directly observed therapy (DOT) or self-administered therapy (SAT) in Kampala, Uganda, and classified them using the Common Terminology Criteria for Adverse Events. We assessed AE timing and summarized related clinical actions including lab tests, diagnoses made, medications prescribed, and treatment interruptions.Results Among 1655 PLHIV treated between July 2020-September 2022, 270 (16.3%) reported 451 events; main issues included general (7%), nervous system (6%), musculoskeletal (5%), gastrointestinal (5%), and dermatologic (3%) disorders. Most (61%) occurred within 6 weeks of initiating 3HP. Among those with events, 211 (78%) required further clinician evaluation, 202 (75%) required laboratory testing, 102 (38%) had medications prescribed, 40 (15%) had treatment paused, and 14 (5%) discontinued 3HP. Women, those multidimensionally impoverished, and DOT recipients were more likely to report an AE. SAT users and later enrollees were more likely to have 3HP interrupted or stopped due to an AE.Conclusions In a routine setting, 3HP was safe with 16% of PLHIV reporting AEs and only 3% requiring temporary or permanent treatment interruption. These findings support 3HP expansion in routine HIV/AIDS care settings for TB prevention.Summary 3HP is being rolled out for TB prevention in high burden countries. We describe the incidence and clinical management of adverse events in a real-world clinical setting among people living with HIV participating in a pragmatic implementation study in Uganda.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03934931Clinical Protocols https://implementationscience.biomedcentral.com/articles/10.1186/s13012-020-01025-8#:~:text=The%203HP%20Options%20Trial%20includes,promote%20adoption%20of%20the%20delivery Funding StatementThe study was funded by the National Heart Lung and Blood Institute of the U.S. National Institutes of Health under award number R01HL144406 (AC).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committees/IRBs of the University of California San Francisco, Makerere University College of Health Sciences School of Public Health, and the Uganda National Council for Science and Technology gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData not publicly available.